Buscar
Lipocine Inc
LPCNAñadir a la lista de seguimiento
2.390USD
-0.070-2.85%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
14.72MCap. mercado
PérdidaP/E TTM
Más Datos de Lipocine Inc Compañía
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Información de Lipocine Inc
Símbolo de cotizaciónLPCN
Nombre de la empresaLipocine Inc
Fecha de salida a bolsaMar 21, 2014
Director ejecutivoPatel (Mahesh V)
Número de empleados16
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 21
Dirección675 S Arapeen Dr Ste 202
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal84108-1295
Teléfono18019947383
Sitio Webhttps://www.lipocine.com/
Símbolo de cotizaciónLPCN
Fecha de salida a bolsaMar 21, 2014
Director ejecutivoPatel (Mahesh V)
Ejecutivos de Lipocine Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Lipocine Inc?
Los cinco principales accionistas de Lipocine Inc son: Mr. John W. Higuchi
¿Cuántas instituciones poseen acciones de Lipocine Inc (LPCN)?
A fecha de 2026Q1, 45 instituciones poseen acciones de Lipocine Inc, con un valor de mercado combinado de aproximadamente 2.08M, lo que representa el 25.27% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1533872.00.